Genzyme Expands Global Infrastructure for Manufacturing, R&D

European Investments to Support Growth of Antibody, Protein Products

26-Sep-2005

Genzyme Corporation announced that it has substantially strengthened its global infrastructure for manufacturing and product development through four major expansion projects in Belgium, Ireland, and the United Kingdom. The new and expanded facilities will support Genzyme's continued growth and innovation, particularly in the areas of antibody and protein-based medicines. Together the projects represent capital investments of more than $500 million over several years, a significant portion of which has already occurred.

The facilities include a new bio-manufacturing plant in Geel, Belgium for the production of monoclonal antibodies and proteins; expansion of Genzyme's manufacturing centers in Waterford, Ireland and Haverhill, UK; and creation of an antibody discovery research facility in Cambridge, United Kingdom.

Genzyme also announced that in addition to producing humanized monoclonal antibodies at its Geel plant, this facility will be used to meet the anticipated demand for Myozyme® (alglucosidase alfa), an enzyme replacement therapy currently under review with U.S. and European regulatory authorities for the treatment of Pompe disease. Production in Geel will augment that at Genzyme's flagship protein manufacturing facility in Boston (Allston), Massachusetts.

Genzyme has a total of seven manufacturing sites in Europe, including a small molecule production site in Liestal, Switzerland, a polyclonal bio-manufacturing site in Lyon, France, and diagnostic manufacturing facilities in Kent, UK and Rüsselsheim, Germany.

Other news from the department science

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous